Join the Attention-Deficit Hyperactivity Disorder (ADHD) group to help and get support from people like you.
Attention-Deficit Hyperactivity Disorder (ADHD) News (Page 6)
Related terms: ADHD, Attention Deficit Disorder, Childhood hyperkinesis, ADD
Study Looks at Trends in Pediatric Mental Health Diagnoses During Pandemic
THURSDAY, May 25, 2023 – Trends in pediatric mental health (MH) diagnoses differed by age and sex over the course of the COVID-19 pandemic, according to a research letter published online May 22 in...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) – Supernus...
FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Miami, FL and Jersey City, NJ - March 23, 2022 --Noven Pharmaceuticals, Inc., awholly-ownedsubsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that the U.S. Food and Drug Administration...
Tris Pharma Announces FDA Approval of Dyanavel XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD
In a clinical study in adults, Dyanavel XR tablets demonstrated bioequivalence to Dyanavel XR (amphetamine) extended-release oral suspension. ADHD patients taking Dyanavel XR oral suspension can...
FDA Approves Qelbree (viloxazine) for the Treatment of ADHD
ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
FDA Approves Azstarys (serdexmethylphenidate and dexmethylphenidate) Capsules for the Once-Daily Treatment for ADHD
CELEBRATION, Fla., March 02, 2021 (GLOBE NEWSWIRE) – KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...
FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD
STAMFORD, Conn.--(BUSINESS WIRE) March 01, 2019 --Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR...
FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD)
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)August 09, 2018 --Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”) a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) announc...
Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension for ADHD
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD
Lexington, Mass., USA – June 20, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved Mydayis (mixed salts of a single-entity amp...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD
DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product c...
Pfizer Receives FDA Approval for QuilliChew ER (methylphenidate hydrochloride) Extended-Release Chewable Tablets
Monday, December 7, 2015 - Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the...
Tris Pharma Receives FDA Approval of Dyanavel XR (amphetamine) Once-Daily Liquid for ADHD in Children
MONMOUTH JUNCTION, N.J., October 20, 2015 – Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved Dyanavel XR (amphetamine), extended-release oral...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
Adderall, bupropion, Vyvanse, amphetamine, Adderall XR, Concerta, methamphetamine, Ritalin, clonidine, view more... Strattera, methylphenidate, modafinil, dextroamphetamine, amphetamine / dextroamphetamine, amantadine, 5-HTP, guanfacine, Focalin, desvenlafaxine, Focalin XR